Better Antifibrotic Decisions Through Cross-Organ Insights
The 10th Antifibrotic Drug Development Summit is the industry's only dedicated forum focused on cross-indication antifibrotic drug development, bringing together 60+ senior leaders across discovery, preclinical, translational, biomarker, and early clinical development.
This landmark anniversary meeting will explore how shared fibrosis biology, predictive biomarkers, human-relevant models, and fibrosis resolution mechanisms can accelerate the development of next-generation therapies across lung, liver, kidney, cardiac, skin, gut, and systemic fibrosis indications.
Featuring 23+ expert speakers from leading organizations including Madrigal Pharmaceuticals, AbbVie, aTyr Pharma, Pfizer, Takeda, Novartis, Arda Therapeutics, and Tribune Therapeutics, attendees will gain actionable insights into target identification, translational strategies, patient stratification, and cross-indication expansion.
The event includes our highly anticipated three interactive pre-conference workshops, two days of scientific presentations, panel discussions, and dedicated networking opportunities designed to foster collaboration across the fibrosis ecosystem.
Who Should Attend?
- Discovery & preclinical scientists
- Translational researchers
- Biomarker specialists
- Clinical development teams
- Fibrosis-focused biotech and pharma leaders
Register and learn more: https://ter.li/hjo705ii
